肝性脊髓病诊断与治疗研究进展

doi:10.3969/j.issn.1672-5069.2012.04.035

摘要/Abstract

摘要： 肝性脊髓病（HM）是由肝病引起的颈髓以下脊髓侧索脱髓鞘病变,临床表现为肢体缓慢进行性对称性痉挛性瘫痪。肝功能不全或肝功能异常是HM的主要原因。该病病理学表现为脊髓锥体束脱髓鞘,并有神经轴索的变性、消失及神经纤维的明显减少,代之以神经胶质填充。临床特征为严重肝病,或伴有反复发作的肝昏迷,脊髓受损后表现为双下肢痉挛性强直和腱反射亢进等。目前对HM尚无特效的预防和治疗方法,且预后不良。

关键词: 肝性脊髓病, 发病机制, 临床表现, 诊断, 鉴别诊断, 治疗

陈贤, 王媛媛, 综述, 聂青和, 审校. 肝性脊髓病诊断与治疗研究进展[J]. 实用肝脏病杂志, 2012, 15(4): 366-368.

[1] Hundt H,Fleming JC,Phillips JT,et al. Assessment of hepatic inflammation after spinal cord injury using intravital microsco. Injury,2011,42（7）:691-696.
[2] Kanazawa H,Fujimoto Y,Teratani T,et al. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One,2011,6（4）:e19195.
[3] Panicker J,Sinha S,Taly AB,et al. Hepatic myelopathy：a rare complication following extrahepatie portal vein occlusion and lienorenal shunt. Neurol India,2006,54（3）:298-300.
[4] Meissner W,Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol,2011,100:193-197.
[5] Stracciari A,Baldin E,Cretella L,et al. Chronic acquired hepatocerebral degeneration:effects of liver transplantation on neurological manifestations. Neurol Sci,2011,32（3）:411-415.
[6] O'Brien J,Staples C,Florin T. Trouble with a shunt:alcohol and spastic paraparesis. Hepatic myelopathy. Gastroenterology, 2010,139（4）:1099,1428.
[7] Gospe SM,Caruso RD,Clegg MS,et a1. Paraparosis,hyperman-ganesaemia,and polycythaemia：a novel presentation of cirrhosis. Arch Dis Child,2000,83（5）:439-442.
[8] Upton MP,Pai RK,Vieth M,et al. Esophageal disease and pathology. Ann N Y Acad Sci,2011,1232:376-380.
[9] Li J,Tao R,Wu W,et al. Transcriptional profiling and hepatogenic potential of acute hepatic failure-derived bone marrow mesenchymal stem cells. Differentiation,2010,80（2-3）:166-174.
[10] Su AP,Cao SS,Le Tian B,et al. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism incirrhosis patients. Clin Res Hepatol Gastroenterol,2012,36（1）: 53-59.
[11] Qu B,Liu C,Guo L, et al. The role of liver transplantation in the treatment of hepatic myelopathy:case report with review of the literature. Transplant Proc,2009,41（5）:1987-1989.
[12] Stutchfield BM,Rashid S,Forbes SJ,et al. Practical barriers to delivering autologous bone marrow stem cell therapy as an adjunct to liver resection. Stem Cells Dev,2010,19（2）:155-162.
[13] Zhang B,Inagaki M,Jiang B,et al. Effects of bone marrow and hepatocyte transplantation on liver injury. J Surg Res,2009,157（1）:71-80.
[14] Yurdaydin C,Idilman R. Hepatic encephalopathy. Euro Gastroenterol Hepatol Rev,2012,7（4）:268-271.
[15] 李梦东,聂青和. 应当重视亚临床肝性脑病的研究. 实用肝脏病杂志,2009,12（4）:241-243.
[16] 聂青和. 重型肝炎并发肝性脑病的诊治进展. 实用肝脏病杂志,2004,7（1）：9-12.
[17] Perryman SV,Jenkins DD,Streetz KL,et al. Hepatic injury and the kinetics of bone marrow-derived hepatocyte transgene expression. Pediatr Surg,2008,43（8）:1511-1519.
[18] Bajaj JS,Cordoba J,Mullen KD,et al. The design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism（ISHEN） consensus statement. Aliment Pharmacol Ther,2011,33（7）:739-747.
[19] Yin YH,Ma ZJ,Guan YH,et al. Clinical features of hepatic myelopathy in patients with chronic liver disease. Postgrad Med J, 2009,85（1000）:64-68.
[20] Nout YS. Gait deficits in liver disease:Hepatic encephalopathy and hepatic myelopathy. Equine Veterin Edu,2011,23（1）:11-13.
[21] Casanova-González MJ,Trapero-Marugán M,Jones EA,et al. Liver disease and erythropoietic protoporphyria:a concise review. World J Gastroenterol,2010,16（36）:4526-4531.
[22] Pinarbasi B,Kaymakoglu S,Matur Z,et al. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible?J Clin Gastroenterol,2009,43（2）:176-181.
[23] Feng Z,Li C,Jiao S,et al. In vitro differentiation of rat bone marrow mesenchymal stem cells into hepatocytes. Hepatogastroenterology,2011,58（112）:2081-2086.
[24] Utku U,Asil T,Balci K,et a1. Hepatic myelopathy with spastic pamparosis. Clin Neurol Neurosurg,2005,107（6）:514-516.
[25] Spengler U. Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Curr Opin HIV AIDS,2011,6（6）:527-533.
[26] Plessier A,Rautou PE,Valla DC. Management of hepatic vascular diseases. J Hepatol,2012,56 （Suppl）:S25-38.
[27] 王文清,柴叶红,杨晓莲,等. 神经肌肉本体促进技术联合功能性电刺激疗法治疗肝性脊髓病（附1例报告）.山东医药,2008,48（4）：15.
[28] 聂青和. 替诺福韦酯与拉米夫定和阿德福韦酯抗HBV疗效对比研究进展. 实用肝脏病杂志,2008,11（6）：429-432.
[29] 聂青和,周天仇. 临床肝病研究十年回顾及展望. 实用肝脏病杂志,2006,9（1）：1-4.
[30] Koo JE,Lim YS,Myung SJ,et a1. Hepatic myelopathy as a presenting neurological implication in patients with cirrhosis and spontaneous splenorenal shunt. Korean J Hepatol,2008,14（1）:89-96.
[31] Caldwell C,Werdiger N,Jakab S,et al. Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transpl,2010,16（7）: 818-826.
[32] Khan AA,Shaik MV,Parveen N,et a1. Human fetal liver derived stem cell transplantation as supportive modality in the management of end stage decompensated liver cirrhosis.Cell Transplant,2010,47（1）:1.
[33] Shang QL,Xiao EH,Zhou QC,et al. Pathological and MR-DWI study of the acute hepatic injury model after stem cell transplantation. World J Gastroenterol,2011,17（23）:2821-2828. [34] 聂青和. 加强病毒性肝炎的基础与临床研究.胃肠病学和肝病学杂志,2007,16（1）：95-99.
[35] 李梦东,聂青和. 应重视肝功能分级及其预后评估的研究. 实用肝脏病杂志,2009,12（6）：401-406.
[36] Baccarani U,Zola E,Adani GL,et al. Reversal of hepatic myelopathy after liver transplantation:fifteen plus one. Liver Transpl,2010,16（11）:1336-1337.

肝性脊髓病诊断与治疗研究进展

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[11]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[12]	曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903.
[13]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[14]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[15]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.